Observational Study
Pre-sarcopenia and Mac-2 Binding Protein glycosylation isomer as predictors of recurrence and prognosis in early-stage hepatocellular carcinoma

Survival prediction by M2BPGi and pre-sarcopenia in patients without HCV after curative RFA for HCC

Masato Nakai, Kenichi Morikawa, Shunichi Hosoda, Sonoe Yoshida, Akinori Kubo, Yoshimasa Tokuchi, Takashi Kitagataya, Ren Yamada, Masatsugu Ohara, Takuya Sho, Goki Suda, Koji Ogawa, Naoya Sakamoto
Abstract

BACKGROUND
The Mac-2 binding protein glycosylation isomer (M2BPGi), a fibrosis marker in various liver diseases, is reportedly a prognostic marker in patients with hepatocellular carcinoma (HCC) who underwent hepatectomy.

AIM
This study aimed to evaluate whether the M2BPGi value, Mac-2 binding protein (M2BP), and pre-sarcopenia before radiofrequency ablation (RFA) could be useful recurrence and prognostic markers in patients with early-stage HCC.

METHODS
In total, 160 patients with early-stage primary HCC treated with RFA were separately analyzed as Hepatitis C virus (HCV)-positive and HCV-negative. Factors contributing to recurrence and liver-related death, including M2BP, M2BPGi, and skeletal muscle mass index, were statistically analyzed. Eighty-three patients were HCV-positive and 77 were HCV-negative.

RESULTS
In HCV-positive patients, only des-γ-carboxy-prothrombin (DCP) ≥ 23 mAU/mL was a significant poor prognostic factor affecting survival after RFA. In HCV-negative patients, M2BPGi ≥ 1.86 cutoff index (COI) was significantly associated with tumor recurrence, but not M2BP. M2BPGi ≥ 1.86 COI (hazard ratio 4.89; 95% confidence interval 1.97–12.18; p<0.001) and pre-sarcopenia (hazard ratio 3.34, 95% confidence interval 1.19–9.37; P = 0.022) were independent significant poor prognostic factors in HCV-negative patients.

CONCLUSION
In HCV-negative patients with primary HCC treated with RFA, lower M2BPGi contributed to lower tumor recurrence rate and longer survival period. Pre-sarcopenia was contributed to poor prognosis independently in HCV-negative patients. These factors might be useful recurrence and prognostic markers for early-stage primary HCC.

**Key Words:** Mac-2 Binding protein, Mac-2 Binding Protein Glycosylation isomer, presarcopenia, primary hepatocellular carcinoma, radiofrequency ablation


**Core Tip:** Hepatocellular carcinoma (HCC) is prone to recurrence, even if cured at an early stage. Pre-sarcopenia has been reported to be a poor prognostic factor in the elderly population. The usefulness of the Mac-2 binding protein glycosylation isomer (M2BPGi) for the treatment of HCC has recently attracted attention. In this study, we investigated the recurrence and prognostic factors in patients who underwent radiofrequency ablation (RFA) for early-stage HCC. Based on our data, pre-sarcopenia and higher M2BPGi, but not M2BP[NM1], were revealed as useful predictors of tumor recurrence and poor prognosis for early-stage primary HCC in HCV-negative patients.

**INTRODUCTION**

Hepatocellular carcinoma (HCC) is an important health problem affecting approximately 900,000 new cancer cases worldwide. In 2020, >800,000 people died from HCC, accounting for approximately 8.3% of cancer deaths [1]. HCC often results from cirrhosis or chronic liver injury caused by background diseases, such as hepatitis C virus (HCV), hepatitis B virus (HBV), primary biliary cholangitis (PBC), autoimmune
hepatitis (AIH), alcoholic liver disease, and nonalcoholic steatohepatitis (NASH). In the last 25 years, treatment for viral hepatitis has made great strides. Notably, HCV has become able to eliminate viruses in almost all cases using direct-acting antivirals (DAAs). Although HBV is still an important risk factor that accounts for approximately 50% of the causes of HCC\textsuperscript{[2]}, the proportion of non-viral liver diseases, especially steatohepatitis, as the causative disease of HCC is increasing. HCC is prone to recurrence, even if cured at an early stage. In the Barcelona Clinic Liver Cancer (BCLC) staging system\textsuperscript{[3-5]}, which is widely used in the treatment of HCC, early-stage HCC is classified as stage 0 or A. BCLC stage 0 is defined as very early stage, for single nodule ≤ 2 cm, Child-Pugh A, Eastern Cooperative Oncology Group Performance status (PS) 0. BCLC stage A is defined as the early stage and is the case of maximum tumor diameter ≤3 cm, number of tumors ≤3, Child-Pugh A-B, and PS 0. Liver transplantation is considered in some unresectable cases of stage A disease, but resection and ablation are often recommended as curative treatments. In recent years, a median overall survival >6 years has been expected for early-stage liver cancer patients undergoing BCLC-0 of A liver resection and ablation\textsuperscript{[6]}. However, even in the case of liver resection for early-stage HCC, the prognosis is poor in cases of portal hypertension\textsuperscript{[7,8]}.

Radiofrequency ablation (RFA) is the most widely used local therapy for HCC treatment. It has been reported that the 4-year local recurrence rate after RFA in the early stage is approximately 5–10% and the 5-year survival rate is approximately 70\%\textsuperscript{[9-13]}. However, it has been reported that cases with impaired liver function and/or bad tumor conditions (large tumor diameter and large number of tumors) have a poor prognosis\textsuperscript{[13]}.

In recent years, many studies have demonstrated that sarcopenia is a poor prognostic factor in patients with chronic liver disease and HCC, because it is related to frailty, loss of function, and low quality of life. Sarcopenia is diagnosed using both muscle power loss and muscle volume loss according to the Japan Society of Hepatology (JSH) diagnostic guidelines\textsuperscript{[14]} or European diagnostic guidelines\textsuperscript{[15, 16]}. Pre-sarcopenia is
defined as muscle volume loss without muscle power loss, and has been reported to be a poor prognostic factor in the elderly population[17].

In addition, the usefulness of the Mac-2 binding protein glycosylation isomer (M2BPGi), also known as Wisteria floribunda agglutinin (WFA)-positive M2BP, which was first reported as a fibrosis marker in HCV patients[18], for the treatment of HCC has recently attracted attention. M2BPGi has been reported as a serum marker for predicting fibrosis not only in HCV but also in other liver diseases, such as HBV[19], AIH[20], PBC[21], and NASH[22]. It has also been reported to be a useful predictor of HCC in various liver diseases[23-27].

In this study, we investigated the usefulness of pre-sarcopenia, M2BPGi, and M2BP as recurrence and prognostic factors in patients who underwent RFA for early-stage HCC.

**MATERIALS AND METHODS**

*Patients and data collection*

A total of 202 patients underwent RFA for primary HCC between 2001 and 2017 at Hokkaido University Hospital, 160 of whom were diagnosed with BCLC stage 0 or A and followed up >6 mo after RFA. Patients with HCV-RNA positive were classified to “HCV-positive” group and HCV-RNA negative were classified to “HCV-negative” group. Blood chemistry data, tumor factors (tumor number, size, and form), and clinical symptoms including ascites, pleural effusion, and hepatic encephalopathy were obtained before RFA.

*Percutaneous RFA procedure*

Percutaneous RFA was performed using a cooled-tip electrode (Cool-Tip; Ablation Systems, Covidien, Boulder, Colombia, CO) after ultrasonography (US) planning. RFA was performed by experienced operators under real-time ultrasound guidance. In some cases, we used a contrast-enhanced US technique or a real-time visual support system to detect the tumor more clearly. Moreover, in some cases, artificial ascites or pleural fluid can prevent thermal injury to extrahepatic organs or avoid the lungs in the tracking line. The ablation time, including three occurrences of roll-off, was 3–12 min.
The ablated lesion and ablative margin were assessed using dynamic computed tomography (CT) or magnetic resonance imaging (MRI) 1–4 days after RFA.

Follow up and definition of recurrence of HCC

Because of the early detection of local and distant recurrence, the first imaging test (dynamic CT or MRI) after RFA was performed 4–8 wk after RFA. After the initial evaluation, follow-up by imaging (dynamic CT or MRI) and serum tumor markers such as alpha-fetoprotein (AFP), lens culinaris agglutinin-A reactive AFP isoform (AFP-L3), and des-γ-carboxy-prothrombin (DCP) were performed every 3–4 mo. Chest computed tomography (CT) was regularly performed to detect distant metastases.

The treatment for recurrence and the definition of deaths

For HCC recurrence, appropriate treatment was performed according to liver cancer treatment guidelines.[28–31] Deaths due to liver cancer, liver failure (including acute or chronic liver failure), hemorrhage due to gastroesophageal varices, and infections associated with spontaneous bacterial peritonitis were defined as liver-related deaths. Deaths other than liver diseases, such as other organ cancers, ischemic heart disease, and pneumonia, were analyzed as survival sensors.

The diagnosis of pre-sarcopenia

Pre-sarcopenia was assessed according to the sarcopenia assessment criteria of the JSH guidelines for sarcopenia in liver disease.[14] Skeletal muscle mass index (SMI) calculated using simple methods. In particular, the left-right sum of the long axis times the short axis of the iliopecto muscles at the level of the third lumbar vertebra (L3) divided by height squared. This method has been reported to correlate well with SMI calculated using a muscle mass measurement software.

Measurement of M2BPGi and M2BP

M2BPGi levels were measured in the conserved serum before RFA and at 1 mo after RFA. M2BPGi detection was based on a lectin-antibody sandwich immunoassay (Sysmex Co., Kobe, Japan) and expressed as a cutoff index (COI), with a range of 0.1–20 COI as previously reported.[30]
M2BP was measured in served serum using enzyme-linked immuno sorbent assay (ELISA) methods (Human Mac-2 binding protein (Mac-2bp) Assay Kit, Immuno-Biological Laboratories Co., Ltd., Fujioka, Japan).

Statistical analysis

Statistical analyses were performed using EZR software \(^{32}\). The Mann–Whitney U test was used to analyze continuous variables. Fisher’s exact test was used for univariate analysis of ordered variables. The Kaplan–Meier method was used to determine recurrence and survival rates, and the log-rank test was used to analyze differences. The median value was used as the cut-off values. For the multivariate analysis of factors related to recurrence and survival, Cox proportional hazards models with stepwise methods using p-values were used.

Ethical considerations

The study protocol was approved by the Institutional Ethics Committee of Hokkaido University (IRB-No. 015-1412) and conformed to the ethical guidelines of the Declaration of Helsinki.

RESULTS

Patient characteristics

As shown in Figure 1, 202 patients underwent RFA for primary HCCs. Of these, 160 cases were classified as BCLC stage 0 or A, and the data were analyzed. Eighty-three patients were classified into the HCV-positive group, and 77 patients were classified into the HCV-negative group. The ratio of older age and Child–Pugh Grade B was higher in the HCV-positive group than in the HCV-negative group. Serum transaminase and fibrosis-4 (FIB-4) index were higher in the HCV-positive group than in the HCV-negative group. In addition, the serum AFP and AFP-L3 Levels were higher in the HCV-positive group. The median tumor diameter and number were not significantly different; however, they tended to be larger in the HCV-positive group than in the HCV-negative group. In contrast, the SMI of the HCV-positive group was significantly lower than that of the HCV-negative group (Table 1).
M2BP and M2BPGi values in HCV-positive and -negative patients

In the HCV-positive group, the median M2BP was 5385 ng/mL and that of M2BPGi was 4.94 COI. On the other hand, in the HCV-negative group, the median M2BP was 2745 ng/mL and that of M2BPGi was 1.86 COI. M2BP and M2BPGi levels were significantly higher in the HCV-positive group than in the negative group (Figure 2). Therefore, we used the median as the cutoff value in the following analysis for each group.

M2BPGi, not M2BP, is the risk factor of recurrence in HCV-negative patients

Next, we examined whether M2BP and M2BPGi could be predictive factors for HCC recurrence in primary HCC patients with BCLC stage 0 or A. M2BP could not be a predictive factor for HCC recurrence in each group, but M2BPGi could be a clinical predictor for HCC recurrence only in the HCV-negative group (Figure 3). Therefore, it is suggested that M2BPGi, but not M2BP, is a predictive factor for HCC recurrence in patients without current HCV infection.

Higher M2BPGi levels and pre-sarcopenia are risk factors for liver-related death in HCV-negative patients

For further analysis, we examined whether M2BP and M2BPGi could be predictive factors of liver-related death in BCLC stage 0 or A. In the HCV-positive group, older age (≥70 years), albumin-bilirubin (ALBI) grade 2 or 3, DCP ≥23 mAU/L, and AFP-L3 ≥10% were factors contributing to a negative effect on survival on univariate analysis. Only DCP≥23 mAU/L was a factor contributing to a negative effect on survival on multivariate analysis, and higher M2BP and M2BPGi were not significant factors for a negative effect on survival in the HCV-positive group (Table 2). In contrast, in the HCV-negative group, M2BPGi ≥1.86 COI and pre-sarcopenia were significant factors contributing to a negative effect on survival (Table 3). In the HCV-negative patient group, M2BPGi, but not M2BP, was a poor prognostic factor (Figure 4). Similarly, pre-
sarcopenia was a poor prognostic factor only in the HCV-negative group (Figure 5). Therefore, higher M2BPGi and pre-sarcopenia were poor prognostic factors in patients without active HCV infection.

DISCUSSION
In this study, we retrospectively analyzed the prognostic factors of early-stage HCC (BCLC stage 0–A) after RFA treatment. Here, we investigated the usefulness of M2BPGi and M2BP as predictors of HCC recurrence and prognosis. As a result, M2BPGi and pre-sarcopenia were useful in HCC recurrence and as prognostic factors in patients without current HCV infection.

Many randomized controlled trials (RCTs)\textsuperscript{[11, 33–40]} have compared the treatment outcomes of hepatectomy and RFA for early-stage HCC, but there are few reports with high quality evidence\textsuperscript{[11, 39, 40]}. In recent years, Ng et al reported no statistically significant difference in recurrence-free survival between hepatectomy and RFA in 109 cases \textsuperscript{[11]}. In the SURF trial, hepatectomy and RFA for HCC with a Child–Pugh score ≤7, tumor diameter ≤3 cm, and tumor number ≤3 were reported to have equivalent recurrence-free survival\textsuperscript{[39]}. Based on the above, RFA has almost the same therapeutic results as hepatectomy for BCLC stage 0/A HCC. Considering that RFA is less invasive than hepatectomy, it is expected to become a standard treatment.

However, it has been reported that local recurrence is observed in approximately 10% of cases in which a sufficient ablation area is obtained by RFA \textsuperscript{[41, 42]}. The risk factors for recurrence have also been reported. Shiina et al reported that, in a large number of cases, a higher DCP was associated with local recurrence. Ectopic recurrence is associated with HCV positivity, Child-Pugh grade B or C, platelet counts ≤100,000, higher AFP, higher DCP, large tumor diameter, and a large number of tumors \textsuperscript{[13]}. Thus, regarding the recurrence of HCC after RFA, not only tumor factors but also factors related to liver function are largely involved. Contrarily, factors related to survival after RFA including younger age, lack of portosystemic shunt, Child-Pugh grade A, lower bilirubin, lower ALBI score, higher albumin, higher prothrombin time, lower AFP, HBV
positivity, lower neutrophil to lymphocyte ratio, small tumor diameter, and low tumor number have been reported in a meta-analysis\textsuperscript{[43]}. Therefore, liver function and pretreatment tumor factors are considered important factors not only for recurrence but also for survival.

In this study, we focused on M2BPGi and muscle mass, which are not direct tumor factors and liver function. M2BP is a secreted glycoprotein of approximately 90 kDa that was originally reported as a ligand for galectin \textsuperscript{[44]}. The serum concentration of M2BP has been reported to increase in various cancers, such as breast and lung cancers\textsuperscript{[45]}. Furthermore, Kamada \textit{et al} reported its usefulness as a marker of liver fibrosis in patients with non-alcoholic fatty liver disease \textsuperscript{[46]}. M2BPGi has a sugar chain with an affinity for WFA and distinguishes the glycan structure of WFA-detectable M2BP. The usefulness of M2BPGi as a marker of liver fibrosis in patients with HCV infection was reported in 2013\textsuperscript{[18]}. M2BPGi has also been reported to be useful as a fibrosis marker in various liver diseases\textsuperscript{[19-22]}. However, the M2BPGi value differs depending on the background liver disease, and it has been reported that the predicted cutoff value of META VIR scoring system\textsuperscript{[17]}; The cutoff value of F4 stage was reported as 5.2 COI for HCV, 3.1 COI for HBV, and 0.91 COI for NASH, respectively\textsuperscript{[48]} . M2BPGi is an interferon (IFN) simulated protein, and the amount of M2BPGi decreases after HCV eradication\textsuperscript{[49]}. Therefore, it is suggested that M2BPGi is high in patients currently infected with HCV, even with the same degree of liver fibrosis. In this study, the median values differed significantly between the HCV-positive and HCV-negative patients. The M2BPGi levels were significantly higher in HCV-positive patients than in HCV-negative patients (Figure 2). Therefore, we analyzed the M2BPGi values separately in HCV-positive and HCV-negative patients.

M2BPGi has also been reported as a useful marker for predicting the occurrence of HCC. Specifically, it has been reported as a marker for predicting HCC in HCV \textsuperscript{[23,50]}, HBV \textsuperscript{[19,27,51-55]} and post-HCV eradication cases \textsuperscript{[25,49,56,57]}. In this study, M2BPGi significantly predicted recurrence in HCV-negative cases. In contrast, M2BP level was not be a predictor of recurrence. Progression of liver fibrosis is a risk factor for HCC. As
M2BPGi reflects liver fibrosis, M2BPGi may be indirectly associated with the development of HCC. M2BPGi may show higher levels in HCV cases than in others, even at similar levels of liver fibrosis. This is because the inflammation caused by the current HCV infection might affect the M2BPGi value in the HCV-positive group. Therefore, predicting HCC recurrence may be difficult using the value of M2BPGi only in HCV-positive cases. Based on the results of this study, prediction of cases at high risk for recurrence after RFA was possible in early-stage HCC by focusing on the value of M2BPGi in HCV-negative patients.

Furthermore, M2BPGi has been reported to be a useful marker for predicting the prognosis of patients after HCV eradication \cite{25}, hepatectomy \cite{24, 58} and transcatheter arterial chemoembolization \cite{59}. In this study, we analyzed prognostic factors after RFA for early-stage HCC, focusing on M2BP, M2BPGi, and pre-sarcopenia. In HCV-positive cases, DCP that is one of the serum tumor markers of HCC was a significant poor prognosis factor. In contrast, in HCV-negative cases, M2BPGi and pre-sarcopenia were significant poor prognostic factors, but tumor factors (tumor number, size, form, and serum markers) were not. In addition, M2BP was not a prognostic predictor in either group. M2BPGi levels are affected by various factors, including acute liver failure, and are associated with liver inflammation, damage, and hepatocyte degeneration\cite{60}. Furthermore, M2BPGi was reported to correlate with inflammatory cytokines and was reduced by steroid treatment in patients with autoimmune hepatitis\cite{61}. In HCV-negative cases, high M2BPGi levels may indicate advanced fibrosis or coexistence of inflammation because these cases are not affected by HCV. Therefore, M2BPGi may be a predictor of liver-related death. Notably, M2BPGi was a more sensitive prognostic marker than other liver function markers or fibrosis markers such as ALBI and FIB-4 in HCV-negative patients. Thus, M2BPGi may be a marker that can predict poor prognosis, including the effects of other factors, such as inflammation and liver fibrosis. Patients with chronic liver disease and sarcopenia have a significantly poorer prognosis\cite{62}. Furthermore, it has been reported that in the elderly, pre-sarcopenia cases have a poorer prognosis than non-sarcopenia cases \cite{17}. In this study, pre-sarcopenia
was a significant poor prognostic factor in HCV-negative cases but was not a significant prognostic factor in HCV-positive cases. The reason for this might be related to the fact that HCV-positive patients had significantly less SMI than the HCV RNA-negative patient group (Table 1). Because muscle volume increases after IFN-free treatment in HCV-positive patients\(^{[63]}\) and that HCV elimination suppresses pre-sarcopenia\(^{[64]}\), the current HCV infection itself may contribute to pre-sarcopenia. In this study, the high proportion of cases of pre-sarcopenia and the elderly may have affected the observation that pre-sarcopenia was not a significant prognostic factor in HCV-positive cases.

This study has several limitations. First, it was a retrospective observational study involving a single hospital and a small number of patients. Second, SMI was evaluated using only the simple CT method. Further studies with larger patient numbers and multicenter evaluations are needed.

**CONCLUSION**

In the near future, almost all HCVs will be eradicated by DAA treatment. Henceforth, almost no HCC cases were derived from the current HCV infection. In this study, we investigated the predictive factors of survival after RFA for HCC in BCLC stage 0 or A patients divided into two groups: HCV-RNA positive and negative. Pre-sarcopenia and M2BPGi, but not M2BP, might be useful tools for the prediction of survival in early-stage HCC in the era of HCV eradication.

**ARTICLE HIGHLIGHTS**

**Research background**

Hepatocellular carcinoma (HCC) is prone to recurrence, even if cured at an early stage. In recent years, many studies have demonstrated that sarcopenia is a poor prognostic factor in patients with chronic liver disease and HCC, because it is related to frailty, loss of function, and low quality of life. Pre-sarcopenia is defined as muscle volume loss without muscle power loss, and has been reported to be a poor prognostic factor in the
elderly population. In addition, the usefulness of the Mac-2 binding protein glycosylation isomer (M2BPGi), also known as Wisteria floribunda agglutinin-positive M2BP, which was first reported as a fibrosis marker in HCV patients, for the treatment of HCC has recently attracted attention.

**Research motivation**

The M2BPGi, a fibrosis marker in various liver diseases, is reportedly a prognostic marker in patients with HCC who underwent hepatectomy. In recent years, many studies have demonstrated that sarcopenia is a poor prognostic factor in patients with chronic liver disease and HCC, because it is related to frailty, loss of function, and low quality of life. Sarcopenia is diagnosed using both muscle power loss and muscle volume loss. Pre-sarcopenia is defined as muscle volume loss without muscle power loss, and has been reported to be a poor prognostic factor in the elderly population.

**Research objectives**

In this study, we investigated the usefulness of pre-sarcopenia, M2BPGi, and M2BP as recurrence and prognostic factors in patients who underwent RFA for early-stage HCC.

**Research methods**

202 patients underwent radiofrequency ablation (RFA) for primary HCCs. Of these, 160 cases were classified as BCLC stage 0 or A, and the data were analyzed. Eighty-three patients were classified into the HCV-positive group, and 77 patients were classified into the HCV-negative group.

**Research results**

In HCV-positive patients, only des-γ-carboxy-prothrombin (DCP) ≥ 23 mAU/mL was a significant poor prognostic factor affecting survival after RFA. In HCV-negative patients, M2BPGi ≥ 1.86 cutoff index (COI) was significantly associated with tumor recurrence, but not M2BP. M2BPGi ≥ 1.86 COI (hazard ratio 4.89; 95% confidence
interval 1.97–12.18; p<0.001) and pre-sarcopenia (hazard ratio 3.34, 95% confidence interval 1.19–9.37; P = 0.022) were independent significant poor prognostic factors in HCV-negative patients.

Research conclusions
In HCV-negative patients with primary HCC treated with RFA, lower M2BPGi contributed to lower tumor recurrence rate and longer survival period. Pre-sarcopenia was contributed to poor prognosis independently in HCV-negative patients.

Research perspectives
In the near future, almost all HCVs will be eradicated by DAA treatment. Henceforth, almost no HCC cases were derived from the current HCV infection. Pre-sarcopenia and M2BPGi, but not M2BP, might be useful tools for the prediction of survival in early-stage HCC in the era of HCV eradication.

1
ACKNOWLEDGEMENTS
This work was supported in part by grants from the Ministry of Education, Culture, Sports, Science, and Technology of Japan, the Japan Society for the Promotion of Science, the Japan Agency for Medical Research and Development, and the Ministry of Health, Labor, and Welfare of Japan.
<table>
<thead>
<tr>
<th>ID</th>
<th>Author(s)</th>
<th>Title</th>
<th>Journal/Website</th>
<th>Crossref</th>
</tr>
</thead>
<tbody>
<tr>
<td>8</td>
<td>Akira Asai, Saho Hirai, Keisuke Yokohama, Tomohiro Nishikawa, Hiroki Nishikawa, Kazuhide Higuchi</td>
<td>&quot;Effect of an Electronic Alert System on Hepatitis B Virus Reactivation in Patients Receiving Immunosuppressive Drug Therapy&quot;</td>
<td>Journal of Clinical Medicine, 2022</td>
<td>Crossref</td>
</tr>
<tr>
<td>9</td>
<td></td>
<td></td>
<td><a href="http://www.physiology.org">www.physiology.org</a></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td></td>
<td></td>
<td><a href="http://www.researchgate.net">www.researchgate.net</a></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td></td>
<td></td>
<td><a href="http://www.science.gov">www.science.gov</a></td>
<td></td>
</tr>
<tr>
<td>13</td>
<td></td>
<td></td>
<td><a href="http://www.karger.com">www.karger.com</a></td>
<td></td>
</tr>
</tbody>
</table>